Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. - Wikidata - awgldk - TriplyDB

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

http://www.wikidata.org/entity/Q33359580

about

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer.Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer.Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status.The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.A phase I study of an oral simulated FOLFOX with high dose capecitabine.A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.Recent developments in chemotherapy of advanced gastric cancer.The emerging role of oxaliplatin in the treatment of gastric cancer.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Clinical experiences with G17DT in gastrointestinal malignancies.Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Docetaxel in the treatment of gastric cancer.Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer.Chemotherapy for advanced gastric cancer: slow but further progress.Metastatic gastric cancer treatment: a little slow but worthy progress.

P2860

Q33242985-70D6110A-710E-42CA-8B17-C9435F7C19E2 Q33337970-5F6264FC-A051-4181-B0C3-137CEE824189 Q33361500-66A45774-A4EC-4488-8483-8C38994075C2 Q33366008-648C41A1-F324-40F9-8F70-E44E4C2F17C1 Q33374059-23524168-D620-41C8-BF70-3D706018C430 Q33383287-ED8942C7-ED31-4979-9740-9E928B3C1B05 Q33387294-6237EF85-4749-4672-AA9B-2BE191C1585C Q33387297-6C59FEBD-4023-4255-B59C-6DB7CB31999F Q33389036-2103690D-9376-4D97-8D68-5C42E6C34842 Q33399154-620954BA-17A9-4DA4-B19A-FE9B6F658064 Q33399530-6950BEB8-0034-45C4-BFD7-EC2D82C27347 Q33402018-2D5761C5-E66E-4113-ADC7-5EE7C0930C07 Q33405235-9C6FAC22-F50B-43D8-8CDB-167155B26B2F Q33728364-18A0C84F-60DF-4F4F-B9EA-5FC652355DCE Q33973344-DE7E444D-A11F-4AEF-AA70-1A2A664CCC74 Q34403664-C48809B5-82D6-4DE7-89D3-674E414818DE Q34594956-663514DA-9E94-4E1D-A5AB-86BC82993CDB Q34670947-754007FE-C42E-46EA-8D27-D11D467C88AA Q35076251-BA405CD4-5F6A-4E0B-9415-D5746CA0CEF2 Q35340883-ECC7767C-9930-4CC4-A80E-674C2B507A77 Q35812808-8A23542B-378F-4D89-8477-313D790C8571 Q35948108-03FA613A-432F-45B0-8BC4-F167863607FE Q36090047-50B80F70-8964-4221-816F-7B1D663AC857 Q36376345-8FFB76EB-D40D-462E-A775-6C1174DAA642 Q36376439-CA4AA31E-20C9-4E00-BB62-3D2A9700237F Q36448668-A4E73A80-5031-4464-8CCB-512E4D759E1E Q36459767-8D4336EA-CFF9-4319-B39C-336EF951E4E2 Q36610215-E2FA739E-4549-4D61-BF66-425B1AF91ABD Q36611088-A0CEF56F-E79D-4E0D-B6B4-A5C3CFF26E80 Q36613622-D307DF93-CEDF-44B5-B891-8AE274350F79 Q36614036-A9C00277-B33F-499C-A642-09BE037A4FC4 Q36615060-627C5E45-BF0C-4262-8A87-599A1BD35318 Q36615597-166FE588-945F-4EF8-8FB6-EA1E5703837C Q36615632-A347853A-F4F9-406B-BF33-E53F67EC36EB Q36616503-AB32165F-6F92-4908-8F68-A164B8118585 Q37134006-5171AF9C-8B6A-4A35-B39C-3551DE438D1C Q37174037-AEF97DCB-0F70-4357-A63D-9805783169C8 Q37336375-D2648301-4C11-46D8-B08B-AF87E8FD2B8F Q37446941-E6BD3C75-0199-4BD4-9DD2-A69509986FDC Q38075499-1731F5A7-91E4-42F1-A3B8-F3201B1B0BD8

P2860

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

http://www.wikidata.org/entity/Q33359580

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@ast

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@en

type

label

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@ast

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@en

prefLabel

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@ast

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@en

P1433

Q33359580-B0F8F8F5-AB8E-472A-8F9E-CEF1459DA774

P1476

Q33359580-EE13C4E2-9105-4509-A296-4AD688F2ED15

P2093

Q33359580-03EF7E85-C35B-483A-A5FB-DDE2DB891CC5

Q33359580-17C5774E-45BC-4041-A932-E3E910166778

Q33359580-1AB818A7-6D0C-4CE9-BC2D-B07771DACAF7

Q33359580-4896D77F-20A1-4FDB-9C88-7CC5902520C4

Q33359580-5005B33E-3EFD-4B2C-BD75-741EA6C55942

Q33359580-5DD70CD4-3D72-40FF-844A-B6C473A97608

Q33359580-6EAF42EB-7A3C-4DAE-BB3D-16B134D58F61

Q33359580-7E974A2D-70A3-4159-ABA2-5AFFF1D4F009

Q33359580-B2DF5C46-D36A-4241-A28C-534F2B5D0C7D

Q33359580-CF3B461F-79D8-4074-A414-6C8381EAF388

P304

Q33359580-F0D15C6E-4BDE-49EF-B8CE-3EFC921F58B7

P31

Q33359580-E9D78EE8-F873-4826-8DFD-246BCC2B056F

P356

Q33359580-90ED1578-38F5-4418-992E-921E615721B0

P407

Q33359580-EB63CBF5-8C1E-4C3E-8410-77B54F06AEDB

P433

Q33359580-B4EF8707-58FC-4419-A06F-F46FD5BF0A62

P478

Q33359580-ED58A602-6935-4763-BBE6-94D4B76F95FE

P50

Q33359580-3920191B-ECE4-4ACD-82FF-81D6A93417E0

P577

Q33359580-0D9EEB73-0C58-4A80-89F9-505A7BF2F136

P698

Q33359580-D5246512-E362-43D1-826F-009D99210DBC

P921

Q33359580-ECF206E4-F81C-4D76-A71D-9129BAE1457E

P356

JCO.2004.07.042

P1433

Journal of Clinical Oncology

P1476

Phase II trial of biweekly inf ...... with advanced gastric cancer.

@en

P2093

Akin Atmaca

http://www.w3.org/2001/XMLSchema#string

Alexander Knuth

http://www.w3.org/2001/XMLSchema#string

Andreas Rost

http://www.w3.org/2001/XMLSchema#string

Dirk Jaeger

http://www.w3.org/2001/XMLSchema#string

Elke Jaeger

http://www.w3.org/2001/XMLSchema#string

Gernot Seipelt

http://www.w3.org/2001/XMLSchema#string

Jacqueline Orth

http://www.w3.org/2001/XMLSchema#string

Mathias J Rummel

http://www.w3.org/2001/XMLSchema#string

Sabine Hahnfeld

http://www.w3.org/2001/XMLSchema#string

Salah-Eddin Al-Batran

http://www.w3.org/2001/XMLSchema#string

P304

658-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.07.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Susanna Hegewisch-Becker

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14966088

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial